How National Health Insurance Coverage Policy Affected the Use of Trastuzumab and Rituximab in China: A Bicentric Retrospective Study.
National Health Insurance Coverage
breast cancer
non-Hodgkin lymphoma
rituximab
trastuzumab
utilization
Journal
Risk management and healthcare policy
ISSN: 1179-1594
Titre abrégé: Risk Manag Healthc Policy
Pays: England
ID NLM: 101566264
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
05
2023
accepted:
01
09
2023
medline:
11
9
2023
pubmed:
11
9
2023
entrez:
11
9
2023
Statut:
epublish
Résumé
Cancer is a significant health concern and is China's leading cause of mortality. Targeted therapies, such as trastuzumab and rituximab, have enhanced clinical treatment efficacy. However, their high costs burden patients and healthcare systems considerably. Patient demographic factors further influence the utilization of these expensive drugs. On September 1, 2017, China implemented the National Health Insurance Coverage (NHIC) policy, necessitating additional real-world evidence to assess its impact on patients. Data on human epidermal growth factor receptor 2-positive breast cancer and CD20-positive non-Hodgkin B-cell lymphoma patients were gathered in Jiangsu Cancer Hospital and Fujian Cancer Hospital from September 2015 to August 2019, including demographic and clinical information. All eligible patients were divided into two groups. Univariate analysis and multivariable logistic regression were used to investigate the differences between subgroups. An interrupted time-series regression was used to examine the change in trastuzumab and rituximab utilization percentages. Before and after the NHIC policy, utilization of trastuzumab increased from 61.13% to 75.10%, and the increase was statistically significant. Rituximab therapy increased statistically significantly from 64.79% to 74.88%. The key factor influencing trastuzumab and rituximab use was the NHIC policy. With policy implementation, medical insurance status, occupations, and cancer disease stage affected trastuzumab and rituximab use. The NHIC policy is essential to the utilization of trastuzumab and rituximab, and the patient's income level and repayment abilities continue to impact the use of innovative anti-cancer drugs. Appropriate steps, such as reducing the urban-rural gap and broadening medical insurance coverage, would enable more people to access novel anti-cancer drugs.
Sections du résumé
Background
UNASSIGNED
Cancer is a significant health concern and is China's leading cause of mortality. Targeted therapies, such as trastuzumab and rituximab, have enhanced clinical treatment efficacy. However, their high costs burden patients and healthcare systems considerably. Patient demographic factors further influence the utilization of these expensive drugs. On September 1, 2017, China implemented the National Health Insurance Coverage (NHIC) policy, necessitating additional real-world evidence to assess its impact on patients.
Methods
UNASSIGNED
Data on human epidermal growth factor receptor 2-positive breast cancer and CD20-positive non-Hodgkin B-cell lymphoma patients were gathered in Jiangsu Cancer Hospital and Fujian Cancer Hospital from September 2015 to August 2019, including demographic and clinical information. All eligible patients were divided into two groups. Univariate analysis and multivariable logistic regression were used to investigate the differences between subgroups. An interrupted time-series regression was used to examine the change in trastuzumab and rituximab utilization percentages.
Results
UNASSIGNED
Before and after the NHIC policy, utilization of trastuzumab increased from 61.13% to 75.10%, and the increase was statistically significant. Rituximab therapy increased statistically significantly from 64.79% to 74.88%. The key factor influencing trastuzumab and rituximab use was the NHIC policy. With policy implementation, medical insurance status, occupations, and cancer disease stage affected trastuzumab and rituximab use.
Conclusion
UNASSIGNED
The NHIC policy is essential to the utilization of trastuzumab and rituximab, and the patient's income level and repayment abilities continue to impact the use of innovative anti-cancer drugs. Appropriate steps, such as reducing the urban-rural gap and broadening medical insurance coverage, would enable more people to access novel anti-cancer drugs.
Identifiants
pubmed: 37692767
doi: 10.2147/RMHP.S420899
pii: 420899
pmc: PMC10488736
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1739-1753Informations de copyright
© 2023 Shang et al.
Déclaration de conflit d'intérêts
The authors declare that this work has no conflicts of interest.
Références
Cancer Med. 2021 Jul;10(13):4555-4563
pubmed: 34145980
Eur J Cancer. 2004 Nov;40(16):2488-93
pubmed: 15519524
New Bioeth. 2017 Apr;23(1):95-104
pubmed: 28517989
Soc Sci Med. 2017 Oct;190:11-19
pubmed: 28823943
Front Pharmacol. 2021 Sep 21;12:734637
pubmed: 34630110
J Glob Health. 2019 Dec;9(2):020702
pubmed: 31673344
BMJ Open. 2019 Nov 28;9(11):e031658
pubmed: 31784440
J Hematol Oncol. 2019 Nov 19;12(1):115
pubmed: 31744509
BMC Health Serv Res. 2021 Aug 21;21(1):856
pubmed: 34419013
J Manag Care Spec Pharm. 2019 Dec;25(12):1310-1317
pubmed: 31778624
PLoS One. 2019 Feb 20;14(2):e0211759
pubmed: 30785916
BMJ Glob Health. 2020 Jan 31;5(1):e002256
pubmed: 32133184
J Clin Oncol. 2017 Aug 1;35(22):2482-2489
pubmed: 28471711
Chin Med J (Engl). 2021 Mar 17;134(7):783-791
pubmed: 33734139
Front Public Health. 2021 Jul 05;9:704700
pubmed: 34291034
BMJ Open. 2021 Jun 30;11(6):e044322
pubmed: 34193481
Asia Pac J Public Health. 2014 Mar;26(2):203-14
pubmed: 23162009
Lancet. 2015 Oct 10;386(10002):1484-92
pubmed: 26466052
Breast. 2018 Jun;39:80-88
pubmed: 29631097
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Int J Environ Res Public Health. 2019 Oct 03;16(19):
pubmed: 31623326
Front Public Health. 2023 Feb 22;11:1059878
pubmed: 36908411
Value Health. 2010 Aug;13(5):573-9
pubmed: 20384980
Int J Environ Res Public Health. 2017 Mar 15;14(3):
pubmed: 28294998
Int J Health Serv. 2011;41(1):51-66
pubmed: 21319720
Cancer Causes Control. 2023 Mar 20;:
pubmed: 36939948
Pharmaceuticals (Basel). 2014 Sep 17;7(9):943-53
pubmed: 25232798
Front Oncol. 2022 Oct 28;12:1011052
pubmed: 36387157
Biosci Trends. 2020 Jan 20;13(6):464-468
pubmed: 31875587
Global Health. 2017 Aug 1;13(1):53
pubmed: 28764738
Psychooncology. 2019 Oct;28(10):1971-1977
pubmed: 31293022
J Clin Oncol. 2005 Mar 10;23(8):1614-5
pubmed: 15755966
Transl Cancer Res. 2021 Jan;10(1):509-519
pubmed: 35116280
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153